Atlas Trials

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

Clinical trial NCT04026841 · UNKNOWN

Trial details

NCT number
NCT04026841
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Primary Lung Cancers
Start date
2019-07-30
Primary completion
2020-02-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.